Edition:
United States

Genocea Biosciences Inc (GNCA.OQ)

GNCA.OQ on NASDAQ Stock Exchange Global Market

5.49USD
23 Sep 2016
Change (% chg)

$0.02 (+0.37%)
Prev Close
$5.47
Open
$5.48
Day's High
$5.58
Day's Low
$5.39
Volume
26,424
Avg. Vol
85,161
52-wk High
$10.04
52-wk Low
$2.56

GNCA.OQ

Chart for GNCA.OQ

About

Genocea Biosciences, Inc. is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through... (more)

Overall

Beta: --
Market Cap(Mil.): $155.78
Shares Outstanding(Mil.): 28.37
Dividend: --
Yield (%): --

Financials

  GNCA.OQ Industry Sector
P/E (TTM): -- 42.52 36.60
EPS (TTM): -1.47 -- --
ROI: -50.74 -0.26 13.91
ROE: -61.66 -3.05 14.82

BRIEF-Genocea qtrly loss per share $0.39

* Expects that cash, cash equivalents to be sufficient to fund operating expenses, capex requirements into second half of 2017 Source text for Eikon: Further company coverage:

Aug 04 2016

BRIEF-Genocea appoints Ron Cooper to board of directors

* Genocea appoints Ron Cooper to board of directors Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Jun 09 2016

BRIEF-Genocea reports qtrly loss per share $0.35

* Expects funds will be sufficient to fund operating expenses and capital expenditure requirements into second half of 2017

May 05 2016

BRIEF-Genocea Bio provides positive mid-stage data on genital herpes drug

* Positive 12 month efficacy data from its phase 2 dose optimization trial evaluating gen-003 for treatment of genital herpes

Mar 31 2016

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF79.15 -0.10
Pfizer Inc. (PFE.N) $34.26 +0.11
Merck & Co., Inc. (MRK.N) $62.96 -0.06
Sanofi SA (SASY.PA) €68.45 -0.48
AstraZeneca plc (AZN.L) 5,170.00p +13.00
GlaxoSmithKline plc (GSK.L) 1,653.00p +4.00
Vical Incorporated (VICL.OQ) $3.25 +0.06

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : ValuEngine, Inc.
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : Ford Investor Services, Inc.
$12.00
Provider : Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.